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Purpose: To evaluate the reliability and validity of the Korean version of the 39-item Parkinson’s disease
questionnaire (PDQ-39).
Methods: Cross-cultural adaptation was performed according to the international guidelines: forward
and backward translation, focus group meeting, and a ﬁeld test. With Korean consensus translation
produced, validation was assessed by evaluating reliability and validity. Ninety-three outpatients with
Parkinson’s disease (PD) and 89 healthy aged controls were recruited. Internal consistency reliability was
assessed by Cronbach’s alpha. Validity was assessed by Spearman correlation analysis, t test, factor
analysis, and analysis of variance with Duncan’s multiple range tests.
Results: In the PD group, mean age was 65.13  9.84 years, and mean duration of PD was 42.41  37.01
months. Ceiling and ﬂoor effects ranged 1.1%e2.2% and 1.1%e15.1%, respectively. Cronbach’s alpha of
eight dimensions ranged from .70 to .97. All dimensions were correlated with each other, except for the
stigma dimension. PD patients had signiﬁcantly lower quality of life than healthy aged controls did,
except for the bodily discomfort dimension. Eight dimensions of Korean PDQ-39 loaded on one factor. PD
patients with a Modiﬁed Hoehn and Yarh Staging score of 4 had the worst quality of life. The relation-
ships among the eight dimensions of Koran PDQ-39 and the Modiﬁed Hoehn and Yarh Staging is fair to
good, except for the stigma and social support dimension.
Conclusion: The Korean PDQ-39 was proved to be reliable and valid. Our results suggest that Korean
PDQ-39 could be used in clinical research to assess and evaluate the disease process and its impacts on
health-related quality of life in Korean PD patients.
Copyright  2014, Korean Society of Nursing Science. Published by Elsevier. All rights reserved.Introduction
Parkinson’s disease (PD) is a common neurodegenerative dis-
order affecting 0.37% among general population and 1.47% of the
population over 60 years of age in Korea. These prevalence rates are
similar to those of studies carried out inWestern countries, and age
is the main risk factor for Parkinson’s disease in Korea (Seo et al.,
2007). PD is a progressive, age-related, and degenerative disorder
of the central nervous system, characterized clinically by tremor,
bradykinesia, rigidity, and disturbed postural reﬂexes (Hankey &
Wardlaw, 2008). As the disease progresses, nonmotor syndromes
including disorders of sleep-wake cycle regulation, cognition,chool of Dankook University,
h Korea.
ng Science. Published by Elsevier.regulation of mood and hedonistic tone, autonomic nervous system
function, sensory function and pain perception add signiﬁcantly to
overall disability and also are critical determinants of health-
related quality of life of affected patients (Jankovic & Tolosa,
2007). Health-related quality of life (QoL for short) refers to the
patient’s own appraisal of the impact of the disease and include
physical, psychological and social domains. Its measurement is of
paramount importance to evaluating disease outcomes and in cost-
beneﬁt analyses. QoL assessment helps to identify problems and
may be essential in chronic and disabling diseases such as in PD
(Martinez-Martin, 1998). In addition, QoL assessment contributes
to a better understanding of the disease’s consequences and its
treatment on the patient, and thus helps in decision making. QoL
evaluations reﬂect the patients’ point of view. Many relevant as-
pects related to the emotional and psychosocial well-being of pa-
tients cannot be evaluated appropriately by clinical methods
(Martinez-Martin). Clinical scales of dysfunction assessment, whichAll rights reserved.
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the illness on subjectively assessed function and well-being of pa-
tients (Longstreth, Nelson, Linde, & Munoz, 1992). QoL issues in
nursing care should be considered throughout all stages of the
disease including diagnosis, early disease, moderate disease,
advanced disease, hospice and bereavement. Therefore, neurosci-
ence nurses need to provide longitudinal care plans to promote QoL
in the context of chronic disease by identifying key treatable
symptoms and providing comfort measures based on the principles
of palliative care for patients and families across the healthcare
continuum (Bunting-Perry, 2006; Shin & Hendrix, 2013).
The 39-item Parkinson’s Disease Questionnaire (PDQ-39) will
probably be the most appropriate instrument among QoL in-
struments for PD patients including the Parkinson’s Quality of life
questionnaire, and Parkinson Quality of life questionnaire (Marius,
Ramaker, van Hilten, & Stiggelbout, 2002). The PDQ-39 includes
eight disease dimensions: mobility, activities of daily living (ADL),
emotional well-being, stigma, social support, cognitions, commu-
nication, and bodily discomfort (Jenkinson, Peto, Fitzpatrick,
Greenhall, & Hyman, 1995). It has been widely used in assess-
ment of diverse signs and symptoms of PD or their impact on QoL
(Jenkinson et al., 1995; Marius et al.). It was the ﬁrst speciﬁc and
consistent instrument for the QoL evaluation in PD patients (Zhang
& Chan, 2012). Brieﬂy, the PDQ-39 is identiﬁed as a patient-
assessed instrument, which is feasible, reliable, valid, comprehen-
sive, and sensitive to change. It reﬂects the entire spectrum of
health-related QoL in PD (Damiano et al., 2000; Peto, Jenkinson, &
Fitzpatrick, 1998; Zhang & Chan). Since a ﬁeld study including
clinical research using a QoL instrument will normally be con-
ducted in a number of different countries, the instrument will need
to be translated into other languages. The aims of the translation
process should ensure that all language versions of the instrument
are equally clear, precise, and equivalent in all aspect to the original
language of the instrument (Fayers, & Machin, 2007). Even with its
wide uses, translations, and validations into multiple languages
(Auquier et al., 2002; Bushnell & Martin, 1999; Katsarou,
Bostantjopoulou, Peto, Alevriadou, & Kiosseoglou, 2001; Luo, Tan,
Li, Soh, & Thumboo, 2005; Martinez-Martin & Payo, 1998; Tan,
Luo, Nazri, Li, & Thumboo, 2004; Zhang & Chan), the Korean
translation of the PDQ-39 has not yet been developed, validated
and reported.
We focused on the validation process to ensure that the Korean
PDQ-39 will be equally clear, precise and equivalent to the original
UK English PDQ-39 and have adequate validity and reliability.
Therefore, the objective of this study was to develop the Korean
version of PDQ-39 and to evaluate its reliability and validity for use
in clinical research and application among Korean PD patients.Methods
Study design
This was a psychometric validation study to evaluate reliability
and validity of the Korean version of 39-Item Parkinson’s Disease
Questionnaire (PDQ-39).Setting and sample
This study was conducted at a neurology outpatient center in a
tertiary university hospital in Seoul, Korea. We consecutively
recruited outpatients diagnosed with PD by a neurologist. A total of
102 outpatients with PD were registered at this center at the
beginning of the study. Among these, 93 patients agreed to
participate to this study.To estimate the required sample size for convergent validity
according to the point biserial correlation model by G*Power 3.1.7
program (Faul, Erdfelder, Lang, & Buchner, 2007), a two-sided test
with a signiﬁcance level of .05, a power (1eb) of .80, and the
anticipated difference (effect size) of 0.30 were speciﬁed. The
sample sizewas calculated at 86 per group. For the criterion validity
by Modiﬁed Hoehn and Yahr Staging (mH&Y) according to analysis
of variance, a signiﬁcance level of .05, a power of .90, an anticipated
difference of 0.5, and the number of groups at 6 were speciﬁed. The
required sample size was calculated as 270 in the PD group, so the
limitation of a small sample size have emerged from a total pop-
ulation of 102 PD patients in this study. In addition, a total of 89
healthy aged controls without major comorbidities who were
registered to the dance sports club at a community senior welfare
center in Seoul were recruited for the purpose of assessing validity.
To estimate the required sample size for known groups validity
according to t test, a signiﬁcance level of .05, a power of .90, and an
effect size of 0.5 were speciﬁed. The required sample size was
calculated as 86 per group.
Ethical consideration
Information about the research was given to these participants
and informed consent was obtained. Study protocol and all of the
study procedures were approved by the institutional review board
of Bundang CHA University General Hospital (2007-18A).
Measurements
Demographics and clinical assessment
Demographics and clinical characteristics including age, sex,
educational attainment (years), employment status, disease dura-
tion (months) since PD diagnosis and the disease status by mH&Y
were assessed. The scale is designed to give an estimate of PD
staging (Hoehn, 1992; Hoehn, & Yahr, 1967), and is the most widely
used measure of clinical outcomes as a gold standard (Jenkinson,
Fitzpatrick, & Peto, 1998). The scale ranged from 0 to 5 where
0 meant no evidence of disease, 1.0 meant unilateral disease only,
1.5 meant unilateral disease plus axial involvement, 2.0 meant
bilateral mild disease without impairment of balance, 2.5 meant
mild bilateral disease with recovery on pull test, 3.0 meant mild-to-
moderate bilateral disease, with some postural instability but
physically dependent; 4.0 meant severe disease, but still able to
walk or stand unassisted, 5.0 meant wheelchair bound or
bedridden unless aided (Hoehn). The assessment and diagnosis
using mH&Y was performed by a neurologist at the university
hospital.
PDQ-39 and PDQ-39 Single Index
We translated items and response choices in the original PDQ-
39 consisting of eight dimensions: mobility (10 items), ADL (6
items), emotional well-being (6 items), stigma (4 items), social
support (3 items), cognitions (4 items), communication (3 items),
and bodily discomfort (3 items). Response choices of all questions
were coded as: 0 ¼ never; 1 ¼ occasionally; 2 ¼ sometimes;
3 ¼ often; 4 ¼ always (or cannot do at all, if applicable). Each
dimensionwas calculated as a scale from 0 (no problem at all) to 100
(maximum level of problem). If the response to a question was
missing, no scale score was calculated for that individual for that
dimension. Finally, eight dimension scores of PDQ-39 were sum-
med into PDQ-39 single index (PDQ-39SI) (Jenkinson et al., 1998).
Summary score can prove helpful in providing a guide to the overall
impact of ill health, as measured on questionnaires which provide a
proﬁle of scores (Ware, Kosinski, Bayliss, McHorney, Rogers &
Raczek, 1995). Lower scores indicate better health-related QoL
Table 1 Characteristics of Patients with Parkinson’s Disease (PD) and Healthy Aged Controls (N ¼ 182)
Characteristics PD patients (n ¼ 93) n (%) or M  SD Healthy aged (n ¼ 89) n (%) or M  SD t or c2 p
Age (yr) 65.13  9.84 70.13  6.00 4.11 <.001
Middle-aged (<65) 39 (42.9) 14 (15.9) 16.52 .001
Young old (65e74) 36 (39.6) 57 (64.8)
Old (75) 16 (17.6) 17 (19.3)
Sex
Male 39 (41.9) 45 (51.1) 1.54 .215
Female 54 (58.1) 43 (48.9)
Educational attainment (yr) 8.3  5.6 11.4  4.4 4.21 <.001
Employment status
Employed 21 (22.6) 14 (15.9) 1.29 .256
Unemployed 72 (77.4) 74 (84.1)
Marital Status
Married 63 (67.7) 58 (69.1) 0.04 .852
Never married/divorced/widowed 30 (32.3) 26 (31.0)
Duration of disease (month) 42.41  37.01
Modiﬁed Hoehn & Yahr StagingaScore
1.0 4 (4.3)
1.5 20 (21.5)
2.0 35 (37.6)
2.5 12 (12.9)
3.0 15 (16.1)
4.0 7 (7.5)
Note. a0 means no evidence of disease, 1.0 means unilateral disease only, 1.5 means unilateral disease plus axial involvement, 2.0 means bilateral mild disease without
impairment of balance, 2.5 means mild bilateral disease with recovery on pull test, 3.0 means mild-to-moderate bilateral disease, with some postural instability but physically
dependent, 4.0 means severe disease, but still able to walk or stand unassisted, 5.0 means wheelchair bound or bedridden unless aided.
Table 2 Floor and Ceiling Effects and Internal Consistency Reliability of Korean PDQ-39
Dimension (no. of items) n M  SD Median Range (minemax) % Floor effecta % Ceiling effectb Cronbach’s a
Korea UKc
Mobility (10) 93 39.19  25.34 35.00 5.00e100.00 6.5 1.1 .97 .94
Activities of daily living (6) 93 25.27  23.85 12.50 0.00e100.00 1.1 1.1 .96 .89
Emotional well-being (6) 93 43.32  24.13 37.50 0.00e100.00 1.1 1.1 .93 .93
Stigma (4) 93 28.83  17.31 25.00 0.00e75.00 7.5 2.2 .90 .80
Social support (3) 71 22.07  16.07 25.00 0.00e75.00 8.5 1.4 .70 .69
Cognitive impairment (4) 93 43.21  25.10 37.50 6.25e93.75 4.3 2.2 .89 .70
Communication (3) 93 24.19  16.76 25.00 0.00e75.00 5.4 1.1 .75 .79
Bodily discomfort (3) 93 20.61  17.75 16.70 0.00e91.67 15.1 1.1 .78 .75
PDQ-39SId 93 30.19  15.40 28.40 4.38e81.15 1.1 1.1
Note. PDQ39 ¼ 39-item Parkinson’s Disease Questionnaire; PDQ-39SI ¼ PDQ-39 single index.
a Refers to the proportion having the minimum score.
b Refers to the proportion having the maximum score.
c Jenkinson, Fitzpatrick, and Peto (1998).
d PDQ-39SI is the sum of dimension scores divided by 8.
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original authors to assess PDQ-39. We assisted and guided the
participants to complete the questionnaire (Jenkinson et al.).
Procedure
Translation and adaptation
We obtained a written approval for developing a Korean version
of PDQ-39 from the developer and received the user manual for the
PDQ (Jenkinson et al., 1998). We followed the rigorous international
translation steps based on Fayers and Marchin’s (2007) guideline.
Two trained bilingual Koreans translated the original UK English
PDQ-39 into Korean independently. To evaluate conceptual equiv-
alence and consistency of the items and scales, a group of special-
ists including a neurologist, a research coordinator, and a
biostatistician compared the two translations and reconciled dis-
crepancies until an acceptable equivalence was obtained. After we
completed a forward translation, a pilot test was conducted for
cognitive debrieﬁng. In the pilot test, we compared QoL of 14 PD
outpatients with 10 healthy aged controls who were not part of the
same pool of the ﬁeld test using the Korean PDQ-39. In a pilot test,
we examined whether patients found any item confusing, difﬁcultto understand, ambiguous or annoying in the translation. After
completing the pilot test, we assessed internal consistency reli-
ability using Cronbach’s alpha. For the construct validity, we
assessed the known-groups validation between PD group and
healthy aged group, and assessed convergent validity by Spearman
correlation coefﬁcients among the eight dimensions of PDQ-39. The
forward translation was then reﬁned and ﬁnalized by rewording
some of the items and response choices based on patients’ feed-
back. Two bilinguals of English and Korean independently trans-
lated Korean translation of PDQ-39 into English. Two backward
translations were compared to the original PDQ-39 for conceptual
consistency. The ﬁnal Korean version of the PDQ-39 was then
completed. We performed a ﬁeld testing using the ﬁnal Korean
version of PDQ-39 and assessed its reliability and the validity.
Data analysis
The cross-cultural adaptation included the instrument trans-
lation, forward and backward, an expert consensus meeting and a
pilot test to produce a conceptually equivalent Korean version of
the PDQ-39. We compared QoL of 93 PD patients with 89 healthy
aged controls using a Korean consensus version of the PDQ-39. To
Table 3 Known Groups Validation for Construct Validity
Dimension (no. of items) PD patients (n ¼ 93) M  SD Healthy aged (n ¼ 89) M  SD t p
Mobility (10) 39.19  25.34 10.27  14.00 9.50 <.001
Activities of daily living (6) 25.27  23.85 3.41  5.68 8.57 <.001
Emotional well-being (6) 43.32  24.13 17.31  18.05 8.17 <.001
Stigma (4) 28.83  17.31 7.79  12.04 9.47 <.001
Social support (3) 22.07  16.07 9.67  13.97 5.14 <.001
Cognitive impairment (4) 43.21  25.10 21.06  17.70 6.84 <.001
Communication (3) 24.19  16.76 7.55  12.11 7.64 <.001
Bodily discomfort (3) 20.61  17.75 22.12  17.76 0.57 .572
PDQ-39SIa 30.19  15.40 12.11  9.68 9.47 <.001
Note. PD ¼ Parkinson’s disease; PDQ-39SI ¼ 39-item Parkinson’s disease questionnaire single index.
a PDQ-39SI is the sum of dimension scores divided by 8.
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were examined. The range and distributions of responses to each
item were examined by ceiling and ﬂoor effects. Reliability for in-
ternal consistency of the eight dimensions of the Korean PDQ-39
was assessed by Cronbach’s alpha. For construct validity, known-
groups validation by t test, convergent validity by Spearman cor-
relation analysis, explorative factor analysis and higher-order
principal component factor analysis were performed. In addition,
the relationship among the PDQ-39 dimensions and mH&Y scores
was examined by Spearman correlation analysis for the criterion
validity. PDQ-39 dimensions and PDQ-39SI according to mH&Ywas
examined by analysis of variance with Duncan’s multiple compar-
ison test. All analyses were conducted using SAS (version 9.1; SAS
Institute Inc., Cary, NC, USA). A p value less than .05 indicated sta-
tistical signiﬁcance.Results
Participant demographics
In PD group, themean agewas 65.13 9.84 years, the number of
male and female were 39 (41.9%) and 54 (58.1%), respectively.
The number of patients holding a job was 21 (22.6%), and married
with spouses were 63 (67.7%). The mean duration of disease was
42.4137.01 months. Healthy aged group was older than PD group
(p< .001). This was the result form a purposive sampling of healthy
aged group to show clear differences of the QoL score between PD
group and controls, because age is a risk factor for developing PD
(Seo et al., 2007). Details of the characteristics of study participants
were presented in Table 1.Table 4 Spearman Correlation Coefﬁcients of 39-Item Parkinson’s Disease Question-
naire (PDQ-39) Dimensions for Convergent ValidityFloor effects and ceiling effects
The distribution of item responses of the Korean PDQ (PDQ-39
and PDQ-39SI) was appropriate. There were no high proportions of
either ﬂoor effects (the proportion of having theminimum score) or
ceiling effects (the proportion of having themaximum score) with a
range of 1.1%e15.1% (Table 2).Dimension MBL ADL EWB STG SS COG COM BD
MBL e e e e e e e e
ADL .88** e e e e e e e
EWB .68** .59** e e e e e e
STG .05 .04 .27* e e e e e
SS .48** .32* .55** .36* e e e e
COG .76** .79** .65** .03 .40* e e e
COM .66** .67** .62** .16 .54** .76** e e
BD .49** .47** .57** .29* .53** .52** .50** e
PDQ-39SI .87** .84** .84** .32* .66** .85** .82** .69**
Note.MBL ¼mobility; ADL ¼ activities of daily living; EWB ¼ emotional well-being;
STG ¼ stigma; SS ¼ social support; COG ¼ cognitive impairment;
COM ¼ communication; BD ¼ bodily discomfort; PDQ-39SI ¼ PDQ-39 single index.
*p < .01. **p < .001.Reliability
Internal consistency reliability by Cronbach’s alpha of the PDQ-
39 ranged from .70 to .97. The lowest level of Cronbach’s alpha was
.70, of the social support dimension, and the highest Cronbach’s
alpha was the dimension of mobility (.97). Five dimensions of
mobility, ADL, emotional well-being, stigma, and cognitive
impairment met the standard of reliability above .80. Also, the di-
mensions of social support, communication, and bodily discomfort
exceeded .70. Therefore, the Korean PDQ-39 was identiﬁed as
reproducible (Table 2).Construct validity by known-group validity
PD patients had signiﬁcantly lower QoL than healthy aged
population in the seven dimensions of PDQ-39 (not for the
dimension of bodily discomfort) and PDQ-39SI (all p < .001). The
PD group showed clear differences in QoL scores from those of
healthy aged control. Therefore, the Korean PDQ-39 was identiﬁed
as a valid and sensitive instrument (Table 3).
Construct validity by convergent validity
Seven dimensions of PDQ-39 correlated with each other,
respectively, and met the minimal acceptable item convergent
validity criteria of .40, but not for the dimension of stigma. Also,
eight dimensions of PDQ-39 correlated with PDQ-39SI, respectively
(all p < .01). The coefﬁcients ranged from .66 (social support) to .87
(mobility). The dimension of stigma (.32) did not meet the minimal
item convergent validity criteria of .40, despite showing statistical
signiﬁcance (Table 4).
Construct validity by factor analysis
By performing the exploratory factor analysis and higher-order
principal component factor analysis of the Korean PDQ-39, each
dimension of PDQ-39 loaded on one factor. One factor was pro-
duced which accounted for 55.5% of the variance by exploratory
factor analysis and 55.4% by higher-order principal component
factor analysis. According to the pattern matrix, factor loadings of
the eight dimensions of PDQ-39 were broadly similar. This conﬁrms
the eight-dimension constructs of the PDQ-39 (Table 5).
Criterion validity
The scores of the PDQ-39 and PDQ-39SI by mH&Y were signif-
icantly different. Patients with stage 2.5, 3.0 or 4.0 had poorer QoL
than those of patients with mH&Y of 1.0e2.0. The Spearman
Table 5 Factor Loadings of Eight Dimensions of 39-Item Korean Parkinson’s Disease Questionnaire (PDQ-39)
Dimension Items Korean PDQ-39
by 39 itemsa
Korean PDQ-39
by Dimensionsb
UK PDQ-39
by Dimensionsc
(n¼93) (n¼93) (n¼227)
Mobility 0.87 0.76
Had difﬁculty doing leisure activity 0.78
Had difﬁculty looking after your home 0.87
Had difﬁculty carrying bags of shopping 0.87
Had problems walking half a mile 0.87
Had problems walking 100 yards 0.84
Had problems getting around the house 0.81
Had problems getting around in public places 0.85
Needed to be accompanied when out 0.84
Frightened or worried about falling in public 0.78
Been conﬁned to the house more than liked 0.88
Activities of daily living 0.84 0.76
Had difﬁculty washing yourself 0.87
Had difﬁculty dressing yourself 0.81
Had problems doing up buttons or laces 0.80
Had problems writing clearly 0.80
Had difﬁculty cutting up food 0.80
Had difﬁculty holding a cup 0.87
Emotional well being 0.80 0.76
Felt depressed 0.66
Felt isolated and lonely 0.75
Felt weepy or tearful 0.75
Felt angry or bitter 0.77
Felt anxious 0.73
Felt worried about the future 0.52
Stigma 0.19 0.70
Felt you had to conceal PD 0.18
Avoided eating or drinking in public 0.12
Felt embarrassed by having PD 0.17
Felt worried by other’s reaction to you 0.20
Social support 0.60 0.63
Had problems with close relationships 0.45
Not had support from spouse or partner 0.49
Not had support from friends or family 0.38
Cognitions 0.86 0.76
Unexpectedly fallen asleep during day 0.67
Had problems with concentration 0.83
Felt your memory was bad 0.79
Had distressing dreams or hallucinations 0.72
Communication 0.86 0.72
Had difﬁculty with speech 0.77
Felt unable to communicate properly 0.72
Felt ignored by people 0.48
Bodily discomfort 0.61 0.61
Had painful muscle cramps or spasms 0.56
Had aches and pains 0.43
Felt unpleasantly hot or cold 0.44
Eigen value/ % of variance explained 19.06/55.5% 4.35/55.4% 4.10/55.1%
a Factor loadings by explorative factor analysis.
b Factor loadings by higher-order principal factor analysis.
c UK PDQ-39: United Kingdom PDQ-39 (Jenkinson, Fitzpatrick, and Peto, 1998).
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PDQ-39SI, and mH&Y is fair to good except for the dimension of
stigma and social support (Table 6).
Discussion
We have cross-culturally developed a Korean version of PDQ-
39. The results showed acceptable distribution of item responses
by good ceiling and ﬂoor effects. Also, the Korean PDQ-39 was
reliable as demonstrated by the good internal consistency reli-
ability and valid as demonstrated by the good construct and cri-
terion validity.
In the forward translation, two bilingual Korean translators had
difﬁculty in translating the choices of “Occasionally” and“Sometimes”, because most Korean people used to regard these
response choices as representing similar quantities. Hagell and
McKenna (2003) also indicated the ambiguous distinction be-
tween these response categories. In their study, “occasionally” and
“sometimes” were problematic to ﬁve patients and one clinician.
“Walking half a mile” or “100 yard” were also difﬁcult items to
translate because “mile” and “yard” are not formal measures of
distance in Korea. This distance was converted to meters in the
questionnaire to provide conceptually equivalent meaning of “a
mile” and “100 yard” in the Korean version of PDQ-39. Also, Hagell
and McKenna indicated that several problems were related to item
28 and item 29 in the social support scale, which ask about support
from spouse/partner and support from family/close friends,
respectively. The main problem was a double negative in the
Table 6 Criterion Validity of 39-Item Parkinson’s Disease Questionnaire (PDQ-39) by Modiﬁed Hoehn and Yahr Staging Score
Dimension Stage 1 Stage 1.5 Stage 2 Stage 2.5 Stage 3 Stage 4 F p Spearman’s Spearman’s coefﬁcient
(n¼4) (n¼20) (n¼35) (n¼12) (n¼15) (n¼7) coefﬁcient in UK
MSD MSD MSD MSD MSD MSD in Korea
MBL 36.2515.48a 19.1315.22a 29.5719.35a 54.1717.91b 56.1718.34b 84.298.38c 21.38 <.001 .65** .63**
ADL 28.1323.17a 7.295.04a 16.7915.17a 30.9021.94a 41.6721.94a 72.6214.41b 21.85 <.001 .61** .58**
EWB 21.887.12a 32.0824.60a 36.6719.35a 57.6418.79a 51.6721.29a 78.5711.89b 8.89 <.001 .54** .27*
STG 21.8829.54a 24.6912.90a 30.1817.38a 40.6317.37a 21.2513.94a 33.9319.05b 2.38 .045 .10 .31**
SS 21.886.25a 16.4616.47a 20.1212.68a 30.9021.79a 21.9411.62a 33.3316.67a 1.36 .250 .20 0.16
COG 43.7526.52a 27.5017.13a 34.4619.84a 52.0830.31 a 60.8318.06b 78.576.10c 10.63 <.001 .53** .40**
COM 12.504.81a 17.5015.51a 18.3312.59a 33.3320.41b 32.7813.90b 45.2410.60b 7.60 <.001 .50** .45**
BD 18.7517.18a 15.839.71a 17.1416.66a 27.0823.87a 19.4415.64a 44.0517.82b 3.86 .003 .24* .32**
PDQ-39SI 25.6311.34a 20.0610.82a 25.4110.71a 40.8416.27b 38.2211.93b 58.826.64c 16.09 <.001 .61**
*p < .05. **p < .001.
Note. MBL ¼mobility; ADL ¼ activities of daily living; EWB ¼ emotional well-being; SS ¼ social support; COG ¼ cognitive impairment; COM ¼ communication; BD ¼ bodily
discomfort; PDQ-39SI ¼ PDQ-39 single index; Spearman’s r ¼ Spearman correlation coefﬁcient between modiﬁed Hoehn and Yahr staging score and each dimension of
PDQ-39; UK PDQ-39 ¼ PDQ-39 of United Kingdom English original version (Jenkinson, Fitzpatrick, and Peto, 1998).
a,b,c Analysis of variance with Duncan’s multiple range test where values with the same superscript are not signiﬁcantly different.
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caused some to give the opposite answer to that intended. In
addition, and related more to the content of the items, the sepa-
ration of spouse/partner from family/friends was felt unnecessary
by one patient while four respondents considered item 28 irrele-
vant to those living alone. So we translated “family/friend” into
“family member” except “spouse/relatives” in Korean PDQ-39. In
cognitive testing with 14 Korean PD patients, Cronbach’s alphas of
eight dimensions in PDQ-39 were above .85, and the convergent
validity by Spearman correlation coefﬁcients and known-groups
validity were good.
Field-testing is the ﬁnal stage in the development of a new
translation questionnaire to determine and conﬁrm the accept-
ability, validity, sensitivity, responsiveness, reliability, and general
applicability of the instrument to cultural group (Fayers & Machin,
2007). In this study, after completion of development of new
translated version, a patients-based validation study was carried
out. Both ﬂoor and ceiling effects to examine the range and dis-
tribution of responses to each item of the Korean PDQ were
appropriate with a range of 1.1%e15.1%. Damiano et al. (2000)
reported both ﬂoor effects (0.0%e6.1%) and ceiling effects (0.0%e
29.2%) by showing higher ceiling effect in the dimension of social
support. Hagell, Whalley, McKenna, and Lindvall (2003) reported a
substantial ﬂoor effect of more than 20% (<20% as acceptable
setting point) as evident within three dimensions of PDQ-39
(stigma, social support, & communication). Unlikely, in this
study, the response categories of Korean PDQ-39 were chosen to
use the full range, and were acceptable with both good ﬂoor and
ceiling effects. The intraclass correlation coefﬁcient (ICC) is most
commonly used method for assessing reliability with continuous
data and ordered categorical data that have more than four or ﬁve
response categories to measure the strength of agreement be-
tween repeated measuring (Fayers & Machin). Although most QoL
instruments fail to attain such a demanding level, a reliability
coefﬁcient of at least of .90 is recommended if measurements are
to be used for evaluating individual patients (Nunnally &
Bernstein, 1994). However, for discrimination between groups of
patient, it is usually recommended that the reliability should
exceed .70 (Fayers & Machin). In this study, internal consistency
reliability for the Korean PDQ-39 showed good reliability; it
ranged from .70 (social support) to .97(mobility). The internal
consistency of the dimensions of the Korean PDQ-39 was very
similar to that of other studies previously reported. The ICC ranged
from .69 (social support) to .94(mobility) in the original UKPDQ-39 (Jenkinson et al., 1998), from .73 (bodily discomfort) to .96
(mobility) in the Swedish version (Hagell et al.), from .486
(cognition) to .919 (mobility) in the Chinese version (Zhang &
Chan, 2012). Therefore, the Korean PDQ-39 has shown good ICC
and is reproducible.
Known groups validation showed that PD patients had signif-
icantly lower QoL than healthy aged controls did in the seven
dimensions of PDQ-39 but not for the bodily discomfort dimen-
sion (all p < .001) similar to results from Schrag, Jahanshahi, and
Quinn (2000). The fact that bodily discomfort had no differences
between PD group healthy aged controls might be explained by
the high prevalence of bodily discomfort in the general popula-
tion, and only slightly more common symptoms in patients with
PD (Kind, Dolan, Gudex, & Williams, 1998; Suzukamo, Ohbu,
Kondo, Kohmoto, & Fukuhara, 2006). These results held even af-
ter adjusting for age by additionally conducting analysis of
covariance in this study. Convergent validity among the eight di-
mensions of PDQ-39 and PDQ-39SI by Spearman correlation co-
efﬁcient is fair to good (except for stigma). Therefore, these results
supported the Korean PDQ-39 in having good convergent validity.
However, the stigma dimension was particularly problematic in
this study, so we additionally examined the correlations among
the three items of stigma in the PDQ-39. The results showed good
correlation coefﬁcients among the stigma items. The results from
exploratory factor analysis and principal component factor anal-
ysis of Korean PDQ-39 provided good construct validity. One factor
was produced, which accounted for 55.5% of the variance by
exploratory factor analysis and 55.4% of the variance by principal
component factor analysis. Each dimension of the Korean PDQ-39
loaded broadly on this factor. Unlike the UK PDQ-39, however,
stigma factor loading was lower in the Korean PDQ-39. Based on
the Suzukamo et al.’s (2006) ﬁndings, psychological adjustment
had a greater effect on some dimensions such as stigma and
emotional well-being than on severity of disease in PD. As such,
we would like to recommend further study to elucidate the
inﬂuencing factors potentially contributing the issue of stigma
with consideration to psychological adjustment.
mH&Y as the gold standard was used to assess criterion validity
in this study. The QoL according to mH&Y was signiﬁcantly
different. The patients with stage 2.5, 3.0 or 4.0 had poorer QoL
than that of patients with mH&Y scores of 1.0e2.0. The results
meant Korean PDQ-39 is available by a good level of agreement
with the true value of mH&Y scores. The Spearman correlation
coefﬁcients among eight dimensions of PDQ-39, PDQ-39SI and
H.-J. Park et al. / Asian Nursing Research 8 (2014) 67e74 73mH&Y is fair to good with each other except for stigma and social
support. This result could be explained by Schrag et al.’s (2000)
discussion that stigma and social support did not deteriorate
signiﬁcantly with advancing disease. Fitzpatrick, Peto, Jenkinson,
Greenhall, and Hyman (1997) reported that social support was
not greatly inﬂuenced by disease severity in PD patients. Even a
signiﬁcant result on the criterion validity by mH&Y score, the
limitation of a small sample size of PD group should be pointed
out as a study ﬂaw from a small clinical PD population in this
study.
Data from PDQ-39 can be presented either in proﬁle form or as a
single index ﬁgure called PDQ-39SI. The proﬁle should be of value
in studies aimed at determining the impact of treatment regimens
upon particular aspects of functioning and well-being in patients
with PD. The PDQ-39SI, which was found to be both internally
reliable and valid will provide a summary score of the impact of the
illness on functioning and well-being, and will be of use in the
evaluation of the overall effect of different treatments (Fitzpatrick
et al., 1997). Korean PDQ-39SI has shown the range and distribu-
tion of responses to each item, good convergent validity (.66e.87
except for stigma of .32), good known groups validation, and good
criterion validity.
Our results provide evidence for the appropriateness of the
translation and validation of the Korean PDQ-39 and PDQ-39SI like
the original UK English PDQ-39. So, the impact of treatment or
nursing intervention on speciﬁc dimensions of well-being and
functioning could be evaluated using the PDQ-39. The overall
impact of disease onwell-being and functioning could bemeasured
by PDQ-39SI in patients with PD (Jenkinson et al., 1997).
Conclusion
The results of our study support the application of the Korean
version of PDQ-39 and PDQ-39SI in studies that assess and evaluate
the Korean PD patients. The reliability and validity of the Korean
translation of PDQ-39 were proved for assessing QoL in PD patients.
Our study suggested that the validated Korean PDQ-39 instrument
could be used to determine the impact of the longitudinal care
plans that promote QoL on PD patients as an essential outcome in
the nursing practice and nursing studies for patients and families
across the healthcare continuum.
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